Cargando…
Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer
BACKGROUND: Insulin-like growth factor 1 receptor (IGF-1R) regulates cell growth, proliferation, and apoptosis. Adenocarcinoma and never-smokers have a higher expression of IGF-1R, which is associated with worse overall survival. Dalotuzumab-MK0646 (D) is a humanized monoclonal antibody that targets...
Autores principales: | Huang, Chao H., Williamson, Stephen K., Neupane, Prakash, Taylor, Sarah A., Allen, Ace, Smart, Nora J., Uypeckcuat, Adelina M., Spencer, Sarah, Wick, Jo, Smith, Holly, Van Veldhuizen, Peter J., Kelly, Karen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710681/ https://www.ncbi.nlm.nih.gov/pubmed/26793618 http://dx.doi.org/10.3389/fonc.2015.00301 |
Ejemplares similares
-
Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer
por: Becker, Marc A., et al.
Publicado: (2016) -
Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer
por: Doi, Toshihiko, et al.
Publicado: (2013) -
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
por: Abdel-Wahab, Reham, et al.
Publicado: (2018) -
P.0646 The impact of the Covid-19 pandemic on peripartum affective psychopathology
por: Pompili, S., et al.
Publicado: (2021) -
In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer
por: LEIPHRAKPAM, PREMILA D., et al.
Publicado: (2014)